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Abstract Opioid receptors are widely distributed in the
human body and are crucially involved in numerous
physiological processes. These include pain signaling in
the central and the peripheral nervous system, reproduc-
tion, growth, respiration, and immunological response.
Opioid receptors additionally play a major role in the
gastrointestinal (GI) tract in physiological and pathophys-
iological conditions. This review discusses the physiology
and pharmacology of the opioid system in the GI tract. We
additionally focus on GI disorders and malfunctions, where
pathophysiology involves the endogenous opioid system,
such as opioid-induced bowel dysfunction, opioid-induced
constipation or abdominal pain. Based on recent reports in
the field of pharmacology and medicinal chemistry, we will
also discuss the opportunities of targeting the opioid sys-
tem, suggesting future treatment options for functional
disorders and inflammatory states of the GI tract.
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PMA Phorbol 12-mirystate 13-acetate
POI Postoperative ileus
POMC Proopiomelanocortin
RFBM Rescue-free bowel movements
RGS4 Regulator of G-protein signaling 4
SA Salvinorin A
SNP Single nucleotide polymorphism
TNBS 2,4,6-trinitrobenzene sulfonic acid
UC Ulcerative colitis
VGCC Voltage-gated calcium channel
Introduction
Opioids are broadly used medical and recreational psy-
choactive substances worldwide. For centuries, they have
been used for acute and chronic treatment of moderate to
severe pain, in particular in cancer patients. Opioids have
also been administered in patients after surgical interven-
tions to achieve sufficient post-operative pain control.
Major limitations of prolonged opioid use result from
severe adverse effects, including slowing of GI motility,
respiratory depression, development of tolerance and
physical dependence.
The analgesic effect of opioids implies their action in
the central nervous system. However, opioids are also
active in the periphery and this encouraged their use for
therapeutic purposes also in the GI tract, like in the treat-
ment of diarrhea or abdominal pain. Identification of opioid
receptors in the GI tract and characterisation of their role in
GI pathophysiology made them an attractive pharmaco-
logical target for numerous pathophysiological conditions.
In this review, we discuss the physiology and pharma-
cology of the opioid system, in particular in the GI tract.
We additionally focus on GI disorders and malfunction,
where pathophysiology is related to the endogenous opioid
system, such as opioid-induced bowel dysfunction (OBD),
opioid-induced constipation (OIC) or abdominal pain.
Based on recent reports in pharmacology and medicinal
chemistry, we will also explore the possibilities of targeting
the opioid system for the treatment of functional disorders
and inflammatory states of the GI tract.
Opioid receptors
The endogenous opioid system is composed of cell surface
receptors [1] and their endogenous ligands [2]. Opioid
receptors were divided into three major types: l (mu,
MOR), d (delta, DOR), and j (kappa, KOR) [2–4]. All
three opioid receptor types were cloned in the 1990s, first
DOR from mice [5], followed by KOR [6, 7] and MOR [8].
Over the years opioid receptors were characterized at
biochemical and pharmacological levels. Further division
into subtypes according to their localization, ligands and
function has been proposed. However, the classification of
opioid receptors into subtypes is still controversial due to
unclear criteria, which would enable their proper catego-
rization [9].
Opioid receptors as members of the G protein-coupled
receptor (GPCR) family
Opioid receptors belong to the family of G protein-coupled
receptors (GPCR), one of the largest protein families in
mammals. Opioid receptors are integral membrane pro-
teins, coupled to heterotrimeric Gi/o proteins. The structure
of opioid receptors consists of seven hydrophobic trans-
membrane domains TM I–VII, three intracellular hydro-
phobic (i1–i3) and three extracellular (e1–e3) loops, a
glycosylated amino and a carboxyl terminus (Fig. 1). The
intracellular loop i3 is identical in 20–23 amino acids in all
opioid receptors [10, 11]. The C-terminal end is composed
of 59, 51, 47 amino acids for MOR, DOR and KOR,
respectively, with highly conserved sequence (identical
10–12 amino acids for all opioid receptors) [12].
It has been demonstrated that the transmembrane
domains TM V-VII are required for ligand binding in DOR
[13]. The other transmembrane domain TM IV and the
extracellular loop e2 are responsible for ligand binding in
KOR, whereas the extracellular loop e1 is a ligand binding































Fig. 1 General structure of G protein-coupled receptors. Opioid
receptors are integral membrane proteins, coupled to heterotrimeric G
proteins. The structure of opioid receptors consists of seven hydro-
phobic transmembrane domains TM I–VII, three intracellular hydro-
phobic (i1–i3) and three extracellular (e1–e3) loops, a glycosylated
amino and a carboxyl terminus
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the C-terminus receptor fragment and a transmembrane
domain TM V are engaged in signal transduction pathways
and participate in mediating opioid receptor–G protein
interactions [15].
Activation of opioid receptors and signal transduction
follow a pattern typical for all GPCRs, which is shown in
Fig. 2. Following ligand binding to the opioid active site,
receptor conformation changes, which activates intracel-
lular G proteins. Each G protein consists of three subunits:
a, b and c. Opioid receptors are coupled with Gai (existing
in three forms), Gao (existing in A and B forms) and Gaz
[16]. b and c subunits form a heterodimer, which consists
of one of five different b and twelve different c proteins
[17]. The role of the Gbc heterodimer is crucial for the
function of Ga, as it enables proper conformation of Ga
while ligand binding to the receptor [18].
The canonical opioid receptor-related signaling pathway
involves the dissociation of the heterotrimeric G protein
into Ga and Gbc subunits, which is followed by the Ga
translocation and further interaction with Kir3 (G protein-
gated inwardly rectifying K? channel). The release of Ga
subunit also inhibits adenylyl cyclase (AC) activity. The
release of Gbc subunit inhibits voltage-gated Ca2? chan-
nels (VGCC, L-type and N-type) and causes activation of
K? channels. By inhibition of N-type VGCCs opioid
receptor agonists inhibit calcium influx into the cell. Other
effectors linked to Gbc include GPCR kinase 2/3 (GRK),
phospholipase Cb (PLCb), phospatidyloinositol-3-kinase
(PI3K), adenylyl cyclase and others [3, 19]. When the Ga
subunit activates the intracellular effectors, GTP hydro-
lyzes to GDP and Ga loses its activity and binds to subunit
Gbc—the recovered complex is inactive and can be further
activated.
Many intracellular proteins, like b-arrestin, calmodulin,
calnexin, filamin A, periplakin, RGS4, ribophorin I or
ubiquitin interact with opioid receptors and may thus reg-
ulate opioid receptor function at a molecular level, like
receptor trafficking, desensitization or endocytosis (for
review see: Georgoussi et al. [20]). For example, b-arrestin
is a key protein in GPCR desensitization because of
blockage of protein–protein interactions, i.e. receptor pro-
motion in clathrin-dependent manner [21]. The lack of
b-arrestin prevents receptor desensitization and the devel-
opment of opioid tolerance after chronic opioid treatment
in vivo [22, 23].
Opioid receptor gene expression
MOR, DOR and KOR are encoded by OPRM1, OPRD1
and OPRK1 genes, respectively [24]. The opioid receptor
genes are highly conserved in the sequence coding the
7-transmembrane fragment, but vary at the carboxyl and
amino termini. This results in differences in the affinity to
opioid ligands and distinct signaling pathways [25]. The
amino acid sequences in opioid receptors are identical in
roughly 60 %, which indicates their common origin [26].
The N-terminus of all opioid receptors and the trans-
membrane domain TMI are encoded by exon 1, while exon 2
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Fig. 2 Opioid receptor-related intracellular signal transduction path-
ways. Opioid receptors are coupled with Gai, Gao and Gaz proteins.
Secondary transmitters include adenylyl cyclase (AC), GPCR kinase
2/3 (GRK), phospholipase Cb (PLCb), and phospatidyloinositol-3-
kinase (PI3K). The release of Gbc subunit also inhibits voltage-gated
Ca2? channels (VGCC, L-type and N-type) and activates K? channels
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is responsible for coding transmembrane domains TMII–IV.
Distal TM domains (TMV–VII) and the intracellular
C-terminus are encoded by exon 3 [27]. All genes encoding
opioid receptors produce multiple mRNA isoforms, what
results from alternative splicing, alternative promoters, but
also various sites of polyadenylation and inclusions of non-
coding sequences [28].
MOR, the major site of action of opioid drugs, is
encoded by the OPRM1 gene located in chromosome 6
(6q25.2.) [29]. The OPRM1 gene possesses 23 transcription
variants and the most common variant (MOR-1O) consists
of 4 exons and encodes 418 amino acids [30]. The differ-
ences between OPRM1 gene variants are highly correlated
with changes in dosage requirements for some exogenous
opioids. These alterations result from occurring polymor-
phisms and include alternative splicing at both ends (30 and
50) of mRNA, combined with heterodimerization of the
receptors. More than 100 single nucleotide polymorphisms
(SNPs) were identified in OPRM1 gene, but their meaning
remains in most cases unclear [25].
Several human genetic polymorphisms and their possi-
ble implications in opioid treatment, as well as the rela-
tionship between these polymorphisms and the clinical
outcome have recently been discussed in an excellent
review by Finco et al. [31]. The most common SNP in the
OPRM1 gene is the substitution A/G (rs 1799971) on
exon 1, which causes a change in the MOR protein amino
acid sequence (Asn?Asp, N40D). This SNP enhances the
binding affinity of b-endorphin at MOR, which causes an
increased potency at the receptor [32]. However, the role of
SNP A118G in antinociceptive action of MOR ligands is
unclear [15, 33–35].
DOR is composed of 372 amino acids. The OPRD1
gene, which encodes DOR, is located on 1p36 and contains
3 exons [36]. Nine DOR-related SNPs, which are common
in several ethnicities, have been reported [37]. Single
nucleotide polymorphism A/G (rs569356) was shown to
increase the activity of OPRD1 promoter, probably by
enhanced binding of the transcription factor [38]. The
elevated expression of OPRD1 may result in increased
rewarding effect of drugs of abuse. Studies on DOR-related
SNPs and their possible role in alcohol dependence and
drug addiction were recently reported [39].
KOR is encoded by OPRK1 gene, which is located on
8q11.2. The major transcription variant possesses four
exons (50 is non-coding) and encodes a protein with 380
amino acids [40]. Several SNPs were classified as SNPs
related to alcohol dependence. The insertion/deletion
(indel) with a net addition of 830 base pairs 1986 bp
upstream of the translational start site in OPRK1 reduces
promoter activity by about half and is associated with
alcohol dependence [41].
Opioid receptors in the central nervous system
A precise quantification of opioid receptor mRNA
expression using absolute quantitative real-time reverse
transcriptase PCR (AQ rt RT-PCR), together with numer-
ous immunohistochemistry studies revealed a wide distri-
bution of opioid receptors in the central nervous system
(CNS) [42]. The highest expression of MOR was observed
in cerebellum, caudate nucleus and nucleus accumbens.
DOR were identified in hippocampus, cerebral cortex,
putamen, caudate nucleus, nucleus accumbens and tem-
poral lobe. The highest expression of KOR was detected in
caudate nucleus, nucleus accumbens, hypothalamic nuclei
and putamen.
In the CNS opioid receptors are expressed in pain-
modulating descending pathways, involving locus coeru-
leus, medulla, and periaqueductal gray area and are mainly
involved in pain signaling and antinociception. Opioid
receptors also occur in midbrain, limbic and cortical
structures and may thus modulate a wide range of other
functions, including memory and stress response.
Activation of opioid receptors attenuates neuronal
activity by pre- and postsynaptic mechanisms, which
include the release of inhibitory neurotransmitters and
changes in neuronal excitability [43]. Opioid receptors and
their ligands are involved in an intense cross-talk with
other endogenous systems. Activation of MOR, which is
most crucial in pain relief, activates central dopamine
reward pathways and may be involved in euphoria. Other
adverse side-effects of MOR activation in the CNS, in
particular upon prolonged administration of MOR agonists,
include addiction, depression, anxiety, and sedation. These
were characterized in many previous reports.
Distribution of opioid receptors in the gastrointestinal
tract
In the periphery, opioid receptors are widely distributed in
neuronal and non-neuronal tissues, including neuroendo-
crine, immune and ectodermal cells [10]. In the GI tract
they are present in smooth muscle cells and at the terminals
of sympathetic and sensory peripheral neurons. It has been
shown that opioid receptors are synthesized in the dorsal
root ganglion and transported centrally and peripherally to
the nerve terminals [44].
The distribution of MOR in the enteric nervous system
(ENS) was summarized by Sternini et al. [45]. As shown
using autoradiography and radiolabeled agonists and
antagonists ([3H]dihydromorphine, [3H]naloxone, and
[3H]loperamide), MOR are expressed in the submucosal
plexus and the myenteric plexus and longitudinal muscle of
ileum from various species (including rat, guinea pig, pig,
J Gastroenterol (2014) 49:24–45 27
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human). Some differences in distribution of MOR among
studied species were also reported (for review see: [46]).
The expression of DOR in murine enteric neurons was
assessed using enhanced green fluorescent protein (GFP),
inserted into OPRD1 gene [47]. The product of insertion, a
80-kDa protein DOReGFP, was detected in esophagus,
gastric corpus and antrum, and small and large intestine.
Further studies revealed that DOReGFP is expressed in
neuropeptide Y (NPY)-positive secretomotor and vasodi-
lator neurons in the submucosal plexus of the small bowel.
Moreover, DOReGFP is also present in excitatory moto-
neurons and interneurons of the myenteric plexus, which
express SP and choline acetyltransferase, and in inhibitory
interneurons and motoneurons expressing nitric oxide
synthase. DOR is also found in nitrergic myenteric neurons
in the mouse colon.
JORs are highly expressed in the periphery, among
others in epidermal keratinocytes and dermal fibroblasts, as
well as in nerve terminals of joints, muscles and viscera.
The expression of KOR was also detected in dorsal and
trigeminal root ganglia [48]. In the GI tract, KORs were
localized to myenteric and submucosal neurons, fibres in
muscle layer, blood vessels and mucosa in rats [49]. Fur-
thermore, AQ rt RT-PCR revealed the presence of KOR in
the liver [47].
Importantly, the opioid receptors were also found in
high amounts on lymphocytes and macrophages [42].
Physiological role of opioid receptors
in the gastrointestinal tract
Many structural and functional components are responsible
for the proper function of the GI tract, including ENS, GI
smooth muscle cells, the intestinal mucosa and blood
vessels. The ENS consists of two plexus—the myenteric
and the submucosal plexus. The localization of the myen-
teric plexus between longitudinal and circular muscles
predestines its involvement in the GI motor activity and its
stimulation increases peristalsis. The submucosal plexus
controls local secretion and absorption activity [50]. Opioid
receptors, which are expressed in the myenteric and the
submucosal plexus play a major role in the regulation of
the GI transit and mucosal transport of fluids and electro-
lytes and maintaining GI homeostasis.
Opioids affect primarily neuronal excitability in the
enteric circuitry via interaction with major transmitters in
the ENS, such as acetylcholine (ACh), SP, neurokinin A
(NKA), ATP, vasoactive intestinal peptide (VIP), NPY or
5-hydroxytryptamine (5-HT) [51]. Results from three dif-
ferent studies furthermore suggested an interaction
between opioid and glutamate receptors in the guinea pig
ileum [52–54]. A recent study by Iwata et al. [55]
suggested that the nitrergic pathway may also be involved
in the opioid-induced actions in the GI tract. It was shown
that the contraction of the mouse ileum induced by mor-
phine administration was inhibited by tetrodotoxin and
NG-nitro-L-arginine, indicating that the potential mecha-
nism of morphine action may be associated with the inhi-
bition of nitric oxide (NO) release from inhibitory nerves.
The major effects of opioid receptor agonists in the GI
tract are reduction of tonic/segmental contractions and
impairment of peristalsis by inhibition of the release of
ACh and SP, as well as decrease of GI secretion by inhi-
bition of the activity of ACh and VIP containing neurons
[56] (Fig. 3). The intestinal mucosa has the ability to
absorb dietary nutrients, water and electrolytes. The active
absorption of Na? and secretion of Cl- across the intestinal
mucosa is critical for maintenance of the water-electrolyte
balance, defense against bacterial infections and digestive
processes [57]. Opioids reduce epithelial secretion and
promote water and electrolyte absorption mainly by acti-
vation of DOR and MOR [58]. Opioid receptor-mediated
increase of cyclic nucleotide concentration stimulates Cl-
secretion and inhibits Na?/Cl- absorption [59].
In consequence, opioids induce stationary motor pat-
terns: inhibit relaxation of the lower esophageal sphincter,
decrease propulsion of smooth muscles in the small and
large intestine, increase pyloric and anal sphincter tonus,
delay gastric emptying and oral-cecal transit time, and
enhance absorption of fluids from intestinal contents.
Because of these involvements, the effects of opioid
treatment result in nausea, vomiting, altered fluid dynamics
and increased GI transit time, constipation, abdominal
discomfort or pain (as summarized in Fig. 4).
Interestingly, opioid receptor agonists can modulate the
GI function through centrally mediated actions at the sites
which are not protected by blood brain barrier (BBB). For
example, it was demonstrated that the activation of MOR
located in the medial subnucleus of the tractus salitarius
(mNTS) affects the GI motor function. The microinjection
of MOR agonists (at doses 1–10 fmol) into mNTS
decreased the intragastric pressure and phasic contractions,
and inhibited gastric motility [60]. The actions of MOR
agonists were associated with the suppression of local
GABA activity, which is known to decrease gastric tone
and motility [61]. In another study, low doses of MOR
agonists (30–300 fmol) microinjected into mNTS area)
affected gastric motility by decreasing intragastric pressure
and phonic contractions. The inhibitory effect of MOR
agonists in mNTS was absent following vagotomy or
pretreatment with a selective MOR antagonist. This sug-
gests the involvement of opioid receptors and their ligands
in vagovagal reflexes through the release of endogenous
opioids in the mNTS area.
28 J Gastroenterol (2014) 49:24–45
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Oligomerization of opioid receptors
Similarly to other GPCR proteins, the opioid receptors can
heteromerize under physiological and pathophysiological con-
ditions in order to form functional dimers, heterodimers and
oligomers [62–64]. Opioid receptors can interact with each other
and can also form complexes with other proteins. For example,
DOR can exist as homodimers and in presence of an agonist the
dissociation of DOR complex occurs. KOR and DOR can also
heterodimerize, but their activity is decreased, when they form a
complex [11]. The role of heterodimerization of opioid receptors
remains unclear, because highly selective ligands for these
heterodimers are not available [65]. However, it was suggested
that heterooligomerization might induce changes in receptor-
related signaling and alter ligand binding [66, 67].
It was suggested that the presence of MOR and can-
nabinoid type 1 receptor (CB1R) heterodimers may result
in altered antinociceptive action of opioids. For example,
the administration of D 9-tetrahydrocannabinol (THC), a
CB1 agonist enhanced the antinociceptive action of
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Fig. 3 Interaction of opioids
with neurotransmitters in the
enteric nervous system. Opioids
reduce tonic/segmental
contractions and impair
peristalsis by inhibition of the
release of ACh and SP. The
decrease of GI secretion is
caused by the inhibition of the
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Fig. 4 Pharmacological and clinical effects of opioids
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tissues, like adrenal glands. Endogenous opioid peptides
derive from three precursor proteins: proopiomelanocortin
(POMC), prodynorphin (PDYN) and proenkephalin
(PENK) (Table 1). POMC is a precursor for a- and
b-endorphin and non-opioid peptides, such as adrenocor-
ticotropic hormone (ACTH), a- and b-melanocyte-
stimulating hormone (MSH), corticotropin-like intermedi-
ate peptide (CLIP) and b-lipotropin (b-LPH). Dynorphin
A and B and neomorphins derive from PDYN. PENK
is a precursor for enkephalins ([Leu5]enkephalin, [Met5]
enkephalin, [Met5]enkephalin-Arg6-Gly7-Leu8, and [Met5]
enkephalin-Arg6-Phe7). Bovine adrenal medulla (BAM)
peptide and peptides E and F are further products formed
from PENK [70].
Opioid peptides are an important link between the
neuroendocrine and immune systems, and their immuno-
modulatory effect may play a significant clinical role in
immune-mediated diseases.
Endogenous opioid peptides have been reported to
inhibit the release of neurotransmitters, such as ACh,
dopamine, norepinephrine in the CNS and in the periphery.
There are many studies reporting the effects of endogenous
opioids on human body, like control of nociception, mood,
and cardiovascular functions, which have been extensively
reviewed elsewhere [71–73]. Here, we discuss the effect of
endogenous opioids in the GI tract and their possible role in
the GI physiology and function.
In the GI tract the endogenous opioid peptides are
present both in neurons and endocrine cells of the mucosa
[11, 74]. Under physiological conditions, endogenous
opioid peptides exert inhibitory effect on gastric emptying
and intestinal motility. Opioid peptides also decrease bili-
ary, pancreatic and intestinal secretions [75].
Enkephalins
Enkephalins are short peptides, which are produced mainly
by the pituitary, adrenal glands and the pancreas. In the GI
tract enkephalins are also formed in gastric and intestinal
endocrine cells [76]. There are two enkephalins, which play a
major role in molecular signaling through opioid receptors,
[Leu5]enkephalin and [Met5]enkephalin. Both peptides are
potent DOR agonists, and additionally possess some affinity
at MOR. The major physiological effect of enkephalins is
antinociception and inhibition of pain signaling in the CNS
and the periphery, including the GI tract [11, 74].
Enkephalins were also found to be synthesized in leu-
kocytes and may thus participate in inflammatory response.
Owczarek et al. [77] found recently that the serum level of
[Met5]enkephalin were decreased in patients with inflam-
matory bowel diseases (IBD) in comparison to healthy
volunteers. Higher levels of [Met5]enkephalin were found
in colonic biopsies collected from inflammatory lesions
from patients with IBD, compared to biopsies from non-
inflamed colon.
DAMGO, a synthetic MOR agonist, which structure is
based on enkephalin, was studied in a rat model of visceral
pain (i.p. and i.c.v. injections of 2 % acetic acid) and
compared to morphine. I.c.v. injection of DAMGO was
more potent than morphine injection in the reduction of
pain. Moreover, administration of naloxone methiodide, a
peripherally acting antagonist, attenuated the antinocicep-
tive action of DAMGO and morphine [78]. In another
study DAMGO was reported to induce suppression of
enhanced excitability of colon dorsal root ganglion neurons
from rats with chronic visceral hyperalgesia, an animal
model used to characterize mechanisms related to irritable
Table 1 Sequences and affinity of endogenous and exogenous opioid peptides





MOR [ DOR [ KOR
Pro-enkephalin [Met5]Enkephalin Tyr-Gly-Gly-Phe-Met DOR [ MOR  KOR
[Leu5]Enkephalin Tyr-Gly-Gly-Phe-Leu




Unknown Endomorphin-1 Tyr-Pro-Trp-Phe-NH2 MOR
Endomorphin-2 Tyr-Pro-Phe–Phe-NH2 MOR
j-casein Casoxin 4 Tyr-Pro-Ser-Tyr-OCH3 MOR
b-conglycinin Soymorphin-5 Tyr-Pro-Phe-Val-Val MOR
Soymorphin-6 Tyr-Pro-Phe-Val-Val-Asn
Soymorphin-7 Tyr-Pro-Phe-Val-Val-Asn-Ala
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bowel syndrome (IBS), induced by i.c. injection of acetic
acid [79].
Endomorphins
Endomorphin-1 (EM-1, Tyr-Pro-Trp-Phe-NH2) and EM-2
(Tyr-Pro-Phe-Phe-NH2) are two endogenous tetrapeptides
isolated by Zadina et al. [80] from the bovine frontal cortex
and human brain. EMs possess the highest affinity at MOR
of all known endogenous agonists.
There are several reports on the activity of EMs in the GI
tract. It was demonstrated that EM-1 and EM-2 inhibited
striated and smooth muscle response in the esophagus (with
exception of lower esophageal sphincter) in a naloxone-
reversible manner [81]. In the guinea pig ileum, EMs
decreased the release of ACh in LMMP preparations [82, 83].
Furthermore, EMs inhibited longitudinal muscle con-
tractions in the mouse distal colon and evoked contractile
response in circular muscle of proximal and mid colon. It
was also observed that b-FNA (3 9 10-6) and naloxon-
azine (10-6) abolished EM-1-induced contractions, sug-
gesting the involvement of MOR receptor subtypes in
contractile responses induced by EM-1 [84].
Some studies suggest an immunomodulatory role of EMs in
the GI tract. The effect of EM-2 on rat peritoneal macrophage
function was investigated by Azuma et al. [85], who showed
that EM-2 inhibited the production of cytokines, including
TNF-a, IL-10 and IL-12. In addition, EM-2 increased IL-1b
production in phorbol 12-mirystate 13-acetate (PMA)-stimu-
lated macrophages and inhibited chemotaxis.
EMs, similarly to other endogenous opioid peptides, are
prone to rapid degradation and, therefore, studies on their
role in the GI tract are limited. Recently, several new EM
analogs with improved pharmacological profile and bio-
distribution were reported (for review see: [86]). One of the
novel analogs, obtained by the attachment of lactose to the
N-terminus of EM via a succinamic acid spacer, showed
improved membrane permeability and increased metabolic
stability [87]. Interestingly, the adverse effects of this
modified EM on stool hydration, measured using a castor
oil-induced diarrhea assay and GI motility, assessed using a
charcoal GI transit test were less significant compared to
morphine administration. Furthermore, delayed transit was
not observed in rodents treated with the new compound.
The attractive additional benefit of this modified EM was
that it may be administered orally.
Other opioids
Peptides and their derivatives
Soymorphins. The soymorphins, mainly soymorphin-5, -6,
and -7 (Table 1), are MOR agonists, which were shown to
suppress food intake and intestinal motility after oral
administration in a naloxone-dependent manner [88]. The
inhibitory potency of soymorphins on the GI transit was
assessed using selective agonists and antagonists of 5HT1A
(WAY100135), D2 (raclopride) and GABAB (saclofen)
receptors. The obtained results suggest that soymorphins
inhibit small intestinal motility through the release of
serotonin and activation of 5-HT1A receptors. Then,
dopamine is released and acts via D2 receptors. Finally,
GABA is released, which acts through GABAB receptors.
Casoxin 4. Casoxin 4 is a tetrapeptide MOR antagonist,
which was isolated from the j-casein fraction of bovine
milk (Table 1). It was demonstrated that casoxin-4
reversed morphine-induced inhibition of electrically
induced contraction in isolated small intestine in both mice
and guinea pigs [89]. The MOR component was more
prominent in the guinea pig ileum, while KOR and DOR
components were predominant in the mouse ileum. Cas-
oxin 4 after oral administration failed to attenuate the
inhibitory effect of morphine in the murine small intestine.
[90].
Alkaloids and diterpenes
Morphine. Morphine is a classical opioid analgesic com-
monly used for the treatment of acute and chronic pain. Its
major site of action is MOR, but it also displays a minor
affinity at KOR. Morphine can cross the BBB and act in the
CNS. Therefore, its prolonged and repetitive administra-
tion may cause tolerance, nausea, or sedation [91]. Here we
focus on the beneficiary and adverse effects of morphine in
the GI tract.
Morphine delays GI transit in a MOR-dependent man-
ner, but it remains a matter of debate whether this effect is
mediated by MOR in the CNS, the periphery or both.
Chronic administration of morphine (0.05 mg/kg, s.c.) in
healthy human volunteers caused delayed colonic transit
time. Interestingly, the administration of naloxone-3-
glucuronide (0.16 mg/kg, p.o.), a naloxone metabolite,
reversed the effect of morphine without any impact on
analgesia [92]. Naloxone-3-glucuronide is not absorbed
into systemic circulation, there is no penetration through
the colonic-mucosal blood barrier. This suggests that the
action of opioids in the GI tract is mediated mainly by
peripheral receptors. Highly polar naloxone derivatives
peripherally antagonize the effect of morphine-delayed GI
motility in the perfused isolated rat colon [93]. However,
some studies imply that only the CNS is involved.
The development of tolerance following repeated
exposition to morphine is well defined at the cellular and
molecular level, but is poorly understood in vivo, in par-
ticular in terms of GI function. Chronic administration of
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morphine may produce tolerance in the upper GI tract,
specifically in the circular muscle in the ileum, but not in
the colon [94]. The lack of tolerance to morphine observed
in the colon may underlie constipation and the develop-
ment of the opioid-induced bowel dysfunction (OBD).
It was suggested that a transport protein, glycoprotein P,
might be involved in the development of opioid tolerance,
but its role has not been clearly identified [95–97]. Okura
et al. [98] showed that repeated administration of morphine
in rats reduced intestinal absorption of morphine, subse-
quently decreasing its antinociceptive effects. The decrease
in absorption was related, at least partially, to the stimu-
lation of glycoprotein P-mediated efflux. The up-regulation
of glycoprotein P may thus contribute to the development
of opioid tolerance to morphine and oxycodone after oral
administration. Therefore, the design of opioids without
glycoprotein P substrate activity might be a key to avoid
the development of tolerance during their chronic
administration.
Morphine and other alkaloids may be involved in the
immune response mediated by the opioid receptors in the
GI tract. Peng et al. [99] showed that s.c. implementation of
a morphine slow release pellet suppressed cholera toxin-
specific production of IgA and IgG in fragment cultures of
ileal segments, Peyer’s patches and mesenteric lymph
nodes. It was also found that the effect of morphine in gut-
associated lymphoid tissue was mediated through a TGF-b,
a putative IgA switch factor in the GI tract-dependent
pathway. The inhibition of TGF-b by morphine was
reversed by naltrexone, which confirms an involvement of
opioid receptors in immune responses in the GI tract.
Furthermore, morphine may be involved in the devel-
opment of bacterial infections, induced by Streptococcus
pneumonia, Toxoplasma gondii, Klebisella pneumonia,
Candida albicans and other bacterial strains. Interestingly,
these infections promoted by morphine were shown to be
dependent on MOR [100]. Feng et al. demonstrated that
implementation of 75 mg slow release morphine pellet in
mice was a potent enhancer of an oral infection with Sal-
monella typhimurium, which is used to induce a murine
model of typhoid fever and causes gastroenteritis in
humans. Morphine administered via minipumps (at doses
1–25 mg/kg/day) did not sensitize to Salmonella infection
and inhibited GI transit more potently than the morphine
pellets [101].
Chronic administration of morphine in mice may cause
alterations in virulence expression in Pseudomonas aeru-
ginosa and lead to lethal gut-derived sepsis [102]. The
expression of virulent phenotype against intestinal epithe-
lium (strain of Pseudomonas aeruginosa disrupting protein
PA-I lectin) in response to morphine may be principally
mediated by MOR. However, since a peripherally restric-
ted MOR antagonist MNTX did not delay chemotaxis after
Pseudomonas challenge, it is possible that morphine may
also act on other receptors, including non-opioid.
Interestingly, Glattard et al. [103] hypothesized that
endogenous morphine, which is secreted from human
neutrophils following stimulation by lipopolysaccharide
(LPS) and IL-8 in presence of Ca2?, may be involved in
inflammatory responses. They have also shown that the
endogenous morphine level is elevated in patients with
sepsis.
Salvinorin A. Salvinorin A (SA), a diterpene isolated
from the Mexican plant Salvia divinorum, is a selective
KOR agonist, which displays significant inhibitory and
anti-inflammatory effects in the GI tract. It was observed
that in physiological conditions SA inhibited cholinergic
twitch contractions in mouse and guinea pig small and
large intestine in a KOR- and CB1-dependent manner [104,
105]. Furthermore, SA reversed ileal hypermotility induced
by croton oil [106] or endotoxin [107] administration in
mice. Interestingly, in this latter model the regulatory
action of SA on epithelial barrier function was mediated
via NO-related pathways. Recently our group showed that
SA exhibits anti-inflammatory and anti-nociceptive effects
in murine models of intestinal inflammation [108].
The pharmacology of SA in the GI tract was recently
reviewed [109].
Opioid system in pathophysiological conditions
of the GI tract
Diarrhea
The inhibitory effects of opioids in the GI tract, such as
inhibition of neuronal activity, reduced propulsion and
delay of GI transit have been used for centuries for
example to treat diarrhea. Diarrhea is a change of normal
bowel movement characterized by an increase in the water
content, volume, or frequency of stools.
The classical anti-diarrheal agent, loperamide (Fig. 5),
is an agonist of a putative MOR subtype, which is
expressed in peripheral organs [110]. Loperamide is widely
used in patients with digestive disorders and after radio-
therapy and chemotherapy to control diarrhea. It has poor
capacity for BBB penetration at concentrations required for
anti-diarrheal effect [56]. In the GI tract loperamide causes
intestinal relaxation, which is triggered by the opening of
ATP-sensitive potassium channels. The activation of K?
channels triggers cAMP-PKA signaling pathways, which
induce hyperpolarization of cell membranes and relaxation
of smooth muscles. Opening of ATP-sensitive channels
also reduces concentration of intracellular Ca2?, which is
similar to that observed in OIC [111]. Finally, loperamide
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injected intrathecally induces MOR-mediated analgesia
[112].
Acetorphan (Racecadotril) (Fig. 5) is another drug used
in the treatment of acute or chronic diarrhea. Similarly to
loperamide, acetorphan does not cross BBB. However, it
displays a different mechanism of action, since it does not
affect gut motility [113]. The anti-diarrheal effect of
acetorphan results from inhibition of enkephalinases, pro-
teolytic enzymes degrading endogenous opioids present in
the GI tract. Acetorphan increases concentration of
endogenous opioids in the GI tract and reduces secretion of
electrolytes and water into the gut lumen.
The possible application of opioids in different types of
diarrhea has been suggested. The role of opioid receptors
and their ligands in murine allergic diarrhea has been
studied by Duncker et al. [114]. They observed that the
ovalbumin (OVA)-induced allergic diarrhea was improved
by DAMGO and U50’488, synthetic agonists of MOR and
KOR, respectively. Moreover, DAMGO decreased con-
centration of IFN-c, IL-4, IL-5 and IL-10 after ex vivo
stimulation of mesenteric lymphocytes. In comparison with
U50’488, DAMGO did not decrease plasma level of mouse
mast cell protease-1 (MMCP-1), which is a marker of mast
cell degranulation or total plasma IgE. Interestingly, thy-
moquinone–lipophilic compound in hexanic extract from
Nigella sativa (Black cumin) also exhibited beneficial
effects in allergic diarrhea by activation of opioid recep-
tors. The thymoquinone exhibited anti-inflammatory and
anti-cancer properties and was involved in alleviation of
allergic asthma [115–117]. The results of the study suggest
that opioid receptor-mediated modulation of GI and
immune systems may become a target for future therapies
aiming at alleviation of allergy-based diarrhea symptoms.
Opioid agonists, such as trimebutine or loperamide are
commonly used for treatment of symptoms in diarrhea-
predominant IBS (IBS-D). However, their pharmacological
profile seems less favourable compared to 5-HT3 antago-
nists (5-HT3RAs), like ramosetron, alosetron and cilanse-
tron. As shown by Hirata et al. [118], 5-HT3RAs increased
colonic nociceptive threshold in non-stressed rats, and also
inhibited restraint-induced colonic hyperalgesia and diar-
rhea. The latter effect was not achieved in rats treated with
loperamide [118].
Opioid-induced bowel dysfunction
Chronic administration of opioids, in particular at high
doses, may cause several adverse side effects, mainly
originating in the GI tract (for review see: McNicol [119]).
The major opioid-related group of GI disorders, described
as OBD, affects up to 10–20 % of adolescents and adults
around the world [120].
Several ailments characterize OBD, such as constipa-
tion, abdominal pain, bloating and gastro-esophageal
reflux. The chronic occurrence of OBD symptoms may
cause nausea, fecal impaction, vomiting and critical dis-
turbances in absorption of concomitant drugs. Vomiting
and nausea may lead to further complications, including
pneumonia, while mitigated oral intake can be associated
with malnutrition. Abdominal distention associated with
OBD may affect respiratory function and delay wound
healing [121].
One of the most common side effects resulting from
chronic administration of opioids is constipation. It is
defined as a delay in frequency of intestine movements and
is often accompanied by other symptoms, such as hard and
dry stools, incomplete bowel movements, or straining
during defecation. Since constipation is not always related
to OBD, an additional term for this ailment, OIC, was
introduced [75]. OIC is an adverse side effect of opioid
administration, but some additional factors may influence
its development, e.g. metabolic disorders, including dia-
betes mellitus, hypokalemia, hypercalcemia, and hypothy-
reodism, advanced age, low-fluid intake, or reduced
physical activity ([122], for review see: [123]).
The mechanism of OIC is complex and implies many
factors, but the activation of opioid receptors in the
periphery is critical. In general, opioids induce constipation
through disruption of neurotransmission between enteric
neurons and their targets—smooth muscles and epithelial











Fig. 5 Structures of anti-diarrheal agents, loperamide and acetorphan
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depression of peristaltic contractions, but also in an
increase of GI muscle activity, like increase of resting
muscle tones of sphincters, non-propulsive patterns and
spasms. In addition, opioids increase biliary and internal
anal sphincter tones. Finally, suppression of ongoing dis-
charge in secretomotor neurons in the ENS, resulting in the
inhibition of basal epithelial secretion and increased
absorption of fluids from the intestine, which evoke dry and
hard stools, may also contribute to development of OIC
[124].
The treatment of OIC involves the use of stimulant
laxatives, stool softeners and osmotic agents, but this
classical therapy is often not effective. Lubiprostone
(Fig. 6), which is used in clinical conditions to suppress the
symptoms of OIC and constipation predominant-IBS, is a
bicyclic fatty acid of prostone group and derives from
prostaglandin E1 [125]. Lubiprostone reverses inhibitory
action of opioids on mucosal secretion in human small
intestine by promoting transcellular movement of Cl- from
serosal to luminal area in mucosal epithelia, which
enhances fluid secretion [126]. The driving force for this
increased transport of Cl– into intestinal lumen is provided
by Na/K pump, with Cl- entering the cell across basolat-
eral membrane through Na–K–2Cl co-transporter and other
channels on apical membrane. It was shown that lubipro-
stone evokes Cl- secretion via cystic fibrosis transmem-
brane conductance regulator (CFTR) receptors and cAMP
signaling in human T84 colon cancer cell line. Further-
more, the transport of Cl- is dose-dependent and inhibited
by a CFTR inhibitor [127]. Lubiprostone thus increases
mucosal secretion and liquidity of bowel contents and
enables the avoidance or resolution of OIC by chloride
channels without influencing the opioid receptors [128],
which was confirmed in the studies on mice and guinea
pigs [129]. However, therapy with lubiprostone is associ-
ated with side effects including nausea, diarrhea, abdomi-
nal pain and bloating [130].
Postoperative ileus
Postoperative ileus (POI) is a transient cessation of coor-
dinated bowel function following surgical interventions
[131]. POI is a common complication, which occurs
mainly after abdominal, orthopaedic, or cardiac surgery
and affects the whole GI tract. POI may be triggered by
symphatetic reflexes, inhibitory humoral agents, release of
noradrenaline from gut wall, anaesthesic agents and
inflammation. Furthermore, POI is often induced by enteric
inflammatory response and recruitment of leukocytes to
muscularis of intestine wall, which are responsible for
production of NO, a major inhibitory neurotransmitter in
the GI tract. The levels of prostaglandins, upon cyclooxy-
genase-2 (COX-2) and inducible NO synthase (iNOS)
activation, as well as cytokines, including TNF-a, IL-1b
and IL-6 may also increase in POI [132].
The clinical symptoms of POI are similar to those in
OBD, including abdominal distention, lack of intestinal
movements, and accumulation of gas and fluids in the
intestine. The inhibition of gut motility occurs immediately
after surgery, persists for 2–3 days and resolves sponta-
neously. However, delayed GI recovery may lead to clin-
ically relevant complications, such as poor nutritional
intake, delayed wound healing, infections or pulmonary
dysfunction [133] and impact the time of patient
hospitalization.
Opioid agonists, which are used for the treatment of
post-operative pain, may negatively contribute to POI by
stimulation of MOR in the GI tract and inhibition of
intestinal motility [134], as well as activation of iNOS and
increase in NO release from phagocytes. The major pur-
pose of peripherally acting MOR antagonist (PAMORA)
administration is the mitigation of adverse side effects of
endogenous and exogenous opioids in periphery with
maintenance of analgesic effect in the CNS, mainly due to
a low BBB permeability at therapeutic concentrations
(Fig. 7). There are two drugs on the market that are used
in the management of POI after resection of intestine,
alvimopan and methylnatrexone (MNTX) (Fig. 8). Both
were approved by the Food and Drug Administration
(FDA) and the European Medicine Agency in 2008 for the
treatment of OBD and POI. The critical difference
between both drugs is in their utility: alvimopan is
applied to treat opioid-naı¨ve, while MNTX opioid-treated
patients. Furthermore, alvimopan can be administrated
only up to 8 days due to the possibility of myocardial
events [135].
Alvimopan. Alvimopan is approximately 200 times more
potent at peripheral than central MOR [136]. Acute
administration of alvimopan is used to accelerate the time
to recovery of upper and lower GI after abdominal surgery.










Fig. 6 Structure of lubiprostone
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OIC [137]. Furthermore, alvimopan reduces opioid-
induced nausea and vomiting [138].
Earlier clinical trials with alvimopan were reviewed by
Marderstein et al. [139] and the most recent ones are
summarized in Table 2.
In 2008 a randomized, double-blind, placebo-controlled,
dose-finding study was performed on 522 non-cancer
humans with \3 spontaneous bowel movements per week
and other complications associated with chronic opioid
administration ([30 mg of morphine/day), which were
maintained over 6 weeks [140]. After 3 weeks all patients
treated with alvimopan (0.5 or 1.0 mg once or twice a day,
p.o.) exhibited improvement in spontaneous bowel move-
ments and all additional complications.
The post hoc analysis of four randomized, double-blind,
placebo controlled, phase III trials showed a beneficial
impact of alvimopan on GI recovery in 1409 patients after
bowel resection [150]. Of patients orally treated with alv-
imopan (12 mg at least 30 min, but no longer than 5 h
before surgical intervention), 80 % exhibited GI recovery
on or before 5 postoperative days. Moreover, the GI
recovery and discharge from hospital were improved in
comparison to placebo-controlled patients.
The randomized, placebo controlled phase III trial of
alvimopan for OIC treatment in 512 patients with non-
chronic pain demonstrated that oral administration of alv-
imopan once or twice a day improved bowel movements in
comparison with placebo group [142]. Moreover, treatment
for 12 weeks was tolerant and safe for all patients treated
with alvimopan. The administration of additional drugs,
e.g. laxatives, was not required.
The length of stay in hospital of patients with laparo-
scopic partial colectomies, in which standard postoperative
treatment was aided by alvimopan (12 mg before and 6 mg
twice a day, for max. 7 days after surgery) was signifi-
cantly shorter compared with control group [151, 152].
Finally, the large-scale report of alvimopan used in
treatment of 3525 patients after open or laparoscopic bowel
resection revealed that the administration of alvimopan
reduced the length and costs of hospitalization [153].
Lower incidence of GI morbidity, mortality and intensive
care unit (ICU) stay were also reported.
In 2008 Schmidt et al. [136] evaluated the action of
alvimopan in the presence of the COX-2 inhibitor DFU in a
rodent model of POI. Alvimopan (10 mg/kg, s.c.) reversed
morphine (1 mg/kg)-induced delay in the GI transit, but
had no effect on transit in control animals. In addition, the
morphine-induced delay of the GI transit was not observed
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Fig. 8 Structures of clinically used peripherally acting MOR antag-
onists (PAMORA): alvimopan and methylnaltrexone
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of alvimopan with DFU inhibited the immunosuppressive
action of morphine, suggesting a new strategy for the
treatment of inflammatory response in postoperative
inflamed GI tissues.
Recently, Vaughan-Shaw et al. [154] performed a meta-
analysis, which comprises three clinical studies mentioned
above [144, 145, 150]. This meta-analysis showed that
12 mg of alvimopan p.o. given 2 h before surgery and than
twice a day until discharge significantly accelerates
recovery of GI tract and reduces time to hospital discharge
in patients undergoing open abdominal surgery enrolled in
an Accelerated Recovery Program.
Methylnatrexone (MNTX). MNTX, similarly to alvimo-
pan, antagonizes MOR located in the intestine without any
effect on opioid receptors present in the CNS. MNTX is
less selective at MOR than alvimopan, as it also binds at
KOR [155].
The clinical trials for MNTX are summarized in
Table 3. In a randomized, parallel-group, double-blind,
placebo-controlled trial of 48 healthy human volunteers,
MNTX (0.3 mg/kg/day, s.c.) did not induce any changes in
the GI transit in comparison to placebo [156]. Moreover,
MNTX did not reverse the anti-motility action of codeine
(120 mg/kg/day, for 5 consecutive days).
The clinical efficiency of MNTX was evaluated in
patients with OIC and chronic, non-malignant pain in a
double-blind, randomized, placebo controlled study [159].
In this trial patients received MNTX (12 mg, s.c.), every
day, every other day (alternatively with placebo) or pla-
cebo alone for 4 weeks. Roughly 40 % of patients
reported rescued free bowel movements (RFBM) after C2
of four doses of MNTX, while 30 % had more than 3
RFBMs per week of MNTX administration. In another
study with a larger group of patients (460) exhibiting OIC
in advanced illness, 34 % of patients had RFBMs within
4 h after the first dose of MNTX [161]. In the placebo
group only 10 % patients had RFBMs. The adverse effects
during MNTX treatment were minimal—the most com-
mon was abdominal pain and the drug was safe and tol-
erated by all patients.
Another randomized, double-blind, parallel group, pla-
cebo-controlled study revealed no improvement of life
quality in postcolectomy patients treated with MNTX or
placebo [162]. The drug was intravenously administered in
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two doses (12 or 24 mg) 90 min after surgery and every
6 h for 24 h or 10 days. The primary efficiency end point
was assessed as time from surgery to first intestine move-
ment, and according to length of hospitalization there were
no differences between all groups. The adverse effects
were similar to those observed in other studies, including
abdominal pain, nausea or vomiting. The additional out-
come of this study was that the dose of 24 mg was safe and
well-tolerated by patients.
Finally, in another study, a cohort of 469 patients was
divided into three groups: placebo, MNTX every day and
MNTX alternating with placebo for 4 weeks [160]. The
improvement in constipation was noted for both groups
subcutaneously treated with MNTX.
Recently, Garten et al. [170] reported that MNTX was
administered to an infant with paralytic ileus. The neonate
was 8 days after surgery and treated with fentanyl (2 lg/
kg/h). The first i.v. administration of MNTX (0.15 mg/kg)
resolved intestinal dismobility after 15 min. The neonate
received 5 doses of MNTX and the intestinal transit was
improved without any adverse side effects.
Antanals. Three novel candidates for PAMORA-type
drugs, designated antanal-1, antanal-2 and antanal-2A have
recently been reported by our group [171]. The antanals




















morphine ? 0.3 mg/
kg MNTX





14 0.05 mg/kg morphine
i.v., 19.2 mg/kg
MNTX





137 Patients with nonmalignant pain,
chronic opioid administration








R, P-C 460 12 mg QD or QOD,
4 weeks






Patients after surgery 12 mg or 24 mg, max.
10 days




















s.c. Defecation after 30 min. [165]
DB, R,
P-C




66 1/3/5 mg/kg, 1–3 weeks s.c. Reversal of OIC at
dose = or [5 mg
[166]
DB 82 0.15 mg/kg, 1 month s.c. Improvement in OIC [167]
DB, R,
P-C












OIC 0.15/0.30 mg/kg, s.c. Safe and well-tolerated drug [169]
DB double-blind, R randomized, PG parallel group, P-C placebo-controlled, QD once daily, BID twice daily
J Gastroenterol (2014) 49:24–45 37
123
were shown to exhibit selective antagonist activity at MOR
in the GI tract in vivo and in vitro. The antanals did not
across BBB after i.p. administration in mice and may thus
become valuable drug templates for the design of future
PAMORA-type therapeutics.
Irritable bowel syndrome
IBS involves a dysregulation of interactions between cen-
tral and peripheral nervous system, so called brain-gut axis
[172]. By many, IBS is linked to disturbances in gut mic-
robiota [173]. This disorder is associated with abdominal
discomfort or pain associated with changed bowel habits
for at least 3 days per month in the previous 3 months, with
the absence of another organic disease [174]. In USA,
5–10 % of population suffer from IBS with prevalence
between 20 and 39 years of age [175]. The prevalence of
IBS is 10–20 % worldwide [176]. IBS patients report
numerous extragastrointestinal symptoms such as fibro-
myalgia, irritable urinary bladder, changes in libido and
energy levels [172].
The several types of IBS can be mentioned, they are
associated with changes in colorectal motility. Patients with
IBS suffer from altered bowel habits, ranging from diarrhea,
constipation, alternating diarrhea and constipation or nor-
mal bowel habits. Patients with a clinically prominent
gastrocolonic reflex exert increased postprandial colonic
contractions. Predominant constipation IBS (IBS-C) is
characteristic for patients with increased colonic contrac-
tions. There is also diarrhea-predominant IBS (IBS-D),
which involves patients with reduced colonic contractions
and alternating or mixed IBS subtypes (IBS-A). [177].
The treatment of IBS is still symptomatic, without a
well-defined first-line therapy. One of the drugs applied to
treat IBS is trimebutine (Fig. 9), which is a weak MOR
agonist, but its clinical efficiency is unclear. Recently, the
effect of trimebutine molecule modified with NO2-arginine
residue (NO2-Arg-Trim) was investigated in a rodent
model of IBS [178]. NO2-Arg-Trim displayed significantly
more potent analgesic activity than trimebutine in healthy
and post-colitis rats. The treatment with NO2-Arg-Trim
also increased expression of genes involved in pain and
inflammatory processes, including TNF-a, IL-1b, COX2
and iNOS, in tissue preparations from post-colitis rodents.
Linaclotide is a drug, which is useful in treatment of IBS
and chronic constipation. Linaclotide is a peptide agonist
of guanylate cyclase, which is important in active transport
of Cl- into the intestinal lumen via CFTR channels. This
drug causes increased stool water content and then relief in
constipation [179]. The therapy for IBS was recently
reviewed by Olden [180].
Inflammatory bowel diseases
Inflammatory bowel diseases (IBD) comprise two idio-
pathic ailments—Crohn’s disease (CD) and ulcerative
colitis (UC). It is estimated that 1–2 % of the population
has IBD and it is more common in women than men. It has
been suggested that IBD involves a dysregulation of the
immune response in the intestine evoked by commensal
bacteria, and a genetic and an environmental predisposition
was reported. The development of IBD may also imply a
neural component, such as colonic nerve damage, changes
in mucosal innervation and alterations in neuropeptide
expression, e.g. SP, VIP and CRH [181]. The major ther-
apeutic goals in IBD patients are the control of inflam-
mation and the treatment of symptoms, which include
abdominal pain and altered bowel movements [182].
Abdominal pain is a common symptom of IBD with a
multifactorial etiology, described as a cramping sensation,
varying in intensity and with exacerbations [179]. There are
two types of abdominal pain—somatic, which is musculo-
skeletal and visceral—caused by stretching of the viscera
and obstruction or widely affected inflammation. The
development of visceral pain is associated with hypersen-
sitivity of the primary sensory neurons in GI tract, which is
subsequently has consequences in CNS. The changes in
intrinsic sensory neurons properties and in gene expression
regulation of nociceptive specific proteins lead to sensiti-
zation of primary afferent neurons. These changes con-
tribute to increased production of pro-inflammatory
molecules occurring via neurogenic inflammation, which
are also involved in swelling, edema and vasodilation [183].
Since immune cells express opioid receptors, opioids
may be involved in the regulation of inflammatory pro-
cesses, with MOR ligands playing the most significant
immunomodulatory role. Cabot et al. [184] showed that
inflammation may increase the expression of POMC
mRNA in immune cells, what results in elevated b-
endorphin production and antinociceptive action. MOR
agonists, DALDA and DAMGO, administered s.c.,
improved colitis in mice [182]. Furthermore, MOR-/-








Fig. 9 Structure of trimebutine
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type animals [182]. It was also demonstrated that opioids
regulate the release of pro-inflammatory cytokines (e.g.
IL-12, IL-6, TNF-a) from peritoneal macrophages in mice
[185]. The murine models of colitis proved that MOR exert
anti-inflammatory effect on colon because of regulation of
T cell proliferation and cytokine production [182]. The
upregulation of MOR occurs during IBD with plausible
beneficial effect on accelerated intestinal transit and dura-
tion of the inflammatory process.
It can be helpful in prevention overt pathological
intestinal inflammation [186].
Goldsmith et al. [187] reported that the administration of
the MOR agonist, DALDA protected against DSS-induced
bowel injury in mice by promoting Stat3 phosphorylation
in intestinal epithelial cells, which led to an increased
expression of cytoprotective genes (Reg3b, Ccnd1, Cox2,
myc), enterocyte proliferation and enhanced wound heal-
ing. DALDA may thus be useful in the treatment of dis-
eases associated with intestinal barrier damage, e.g. IBD or
radiation-induced damage.
Recent data suggest that blockade of MOR may also
alleviate inflammation and, therefore, MOR antagonists
have become an attractive target for drug design in the field
of IBD. The anti-inflammatory action of the MOR antag-
onist, naltrexone in the mouse model of DSS-induced
colitis was first described by Matters et al. [188]. Admin-
istration of naltrexone decreased the over-expression of
pro-inflammatory cytokines IL-6 and IL-12 and improved
mucosal structure. Jan et al. [189] showed that the
administration of naloxone significantly inhibited endo-
toxin-induced activation of NF-jB in RAW264.7 cell
culture, which is a major intracellular pathway involved in
the expression of pro-inflammatory molecules. The pro-
posed explanation of naloxone on NF-jB was mediated
mainly by L-type calcium channels than opioid receptors.
Interestingly, the administration of morphine enhanced the
effect of naloxone as an anti-inflammatory compound.
To the best of our knowledge, there is only one clinical
trial using opioids as an anti-inflammatory drug. In the
randomized double-blind placebo controlled study, adult
patients were treated with naltrexone (4.5 mg) or placebo
for 12 weeks [190]. Colonoscopies were performed for all
patients before and after the study and the results were
reported according to the CD activity index (CDAI) scor-
ing system. A significant improvement in GI mucosal
inflammation was observed in patients after naltrexone
therapy. The side effects of naltrexone treatment included
insomnia, diarrhea and abdominal pain.
Sepsis
Bacterial sepsis, which is quite common in patients after
surgical intervention in comparison with controls without
surgery, is an important and unsolved problem in medicine,
which affects, among others, the function of the GI tract.
It seems likely that opioid receptors may be involved in
the development of sepsis and that morphine and other
opioids may act as cofactors in its precipitation. Hilburger
et al. [191] observed that morphine administration in slow-
release pellets in mice caused the escape of Gram-negative
and enteric bacteria (e.g. Proteus mirabilis, Escherichia
coli, Enterococcus faecalis) from GI tract to the liver, the
spleen and peritoneum, and led to septic state. Moreover,
the application of naltrexone blocked the effect of mor-
phine, indicating that opioid receptors are involved in
sepsis development.
The cecal ligation and perforation (CLP) is used as an
animal model of bacterial peritonitis, comparable with human
sepsis. Topcu et al. [192] showed that the administration of
fentanyl caused significant antitransit effects in the presence
of systemic inflammation in rats. Furthermore, a higher anti-
transit effect of fentanyl was observed in rats with CLP than in
the sham group. It was suggested that the peritoneal inflam-
mation evokes sensitization of opioid receptors located in the
myenteric and the submucosal plexuses in peripheral or cen-
tral nerve terminals and increased the effects induced by
administration of exogenous opioids, in particular MOR and
DOR-selective. This is in good agreement with the study by
Nardi et al. [193], who showed that opioid receptor agonists
fentanyl and tramadol alleviated pain in rat CLP model.
However, adverse side effects occurring after their adminis-
tration, such as alteration of cardiovascular parameters and
high mortality, did not allow for their chronic use.
Opioid receptors are a possible pharmacological target
for the treatment of sepsis. Tang et al. [194], using rat CLP
model, showed that DADLE (5 mg/kg, i.p.), a synthetic
analog of [Leu5]enkephalin, protected against lethal endo-
toxemia in a DOR-dependent manner. In addition, concur-
rent and delayed treatment of rats with DADLE (10-6 M)
suppressed LPS-induced apoptosis and necrosis. DADLE
inhibited signal transduction in macrophages after LPS
stimulation via modulation of MAPK and NFjB pathways
and decreased concentration of TNF-a, IFN-c, Il-1b in
serum. The most important observation from the clinical
point of view was that DADLE inhibited the release of
HMBG1, a late pro-inflammatory cytokine which binds to
DNA and is responsible for stimulation of genes involved in
inflammatory response, from macrophages even 4 h after
the onset of inflammation. This observation may encourage
novel treatment strategies of sepsis.
Conclusion and future perspectives
The most anticipated goal of contemporary drug discovery
is the development of a personalized therapy, which
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requires good knowledge of the treated disease at a
molecular and genetic level and involves a careful selection
of drugs, depending on the molecular target in the cells.
The opioid receptor-based personalized therapy would
primarily aim at the inhibition of molecular pathways
responsible for the adverse side effects of opioid ligands,
such as development of tolerance or OBD. Consequently,
opioid peptide gene therapy was extensively studied in the
last few years. The delivery of genes or their fragments
encoding enkephalins, b-endorphin or EMs was already
validated in numerous animal models [195, 196].
Conventional treatment of many GI disorders and mal-
functions is limited to pure overcoming of their symptoms
and associated with adverse side effects of drugs used. For
example, currently available treatment for the intestinal
inflammation, based on 5-aminosalicylate, corticosteroids
and immunomodulators involves attenuation of inflamma-
tory reaction and plain maintenance of this condition.
Peripherally restricted opioids, which would act directly
and indirectly on immune cells, might become important
tools in the modulation of the immune system response and
alleviation of the inflammatory state.
Other novel diagnostic and treatment strategies for GI
disorders, implied by the presence of opioid receptors and
their ligands in the GI tract and their crucial role in GI
physiology and pathophysiology, are currently under
investigation.
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